Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NX-1607 · 1 trial · 14 indications
Phase 1a
Phase 1a
Phase 1b
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation of NX-1607 (monotherapy) | EXPERIMENTAL | Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose. |
| Phase 1a Food Effect | EXPERIMENTAL | Impact of food on NX-1607 bioavailability and tolerability to be evaluated |
| Phase 1b Dose Expansion in platinum-resistant EOC | EXPERIMENTAL | Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma |
| Phase 1b Dose Expansion in advanced gastric/GEJ cancer | EXPERIMENTAL | Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma |
| Phase 1b Dose Expansion in HNSCC | EXPERIMENTAL | Patients with recurrent, locally advanced, or metastatic HNSCC |
| Phase 1b Dose Expansion in recurrent melanoma | EXPERIMENTAL | Patients with recurrent and either metastatic or unresectable Melanoma |
| Phase 1b Dose Expansion in advanced NSCLC | EXPERIMENTAL | Patients with Stage IV NSCLC |
| Phase 1b Dose Expansion in mCRPC | EXPERIMENTAL | Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression |
| Phase 1b Dose Expansion in mixed solid tumor cohort | EXPERIMENTAL | Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL/DLBCL-RT |
| Phase 1a Dose Escalation of NX-1607 in combination with Paclitaxel | EXPERIMENTAL | Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer. |
| Phase 1b Dose Expansion of NX-1607 in combination with Paclitaxel | EXPERIMENTAL | Indications may include but are not limited to, platinum resistant EOC, gastric/GEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer and cervical cancer |
| Phase 1b Dose Expansion in MSS CRC | EXPERIMENTAL | Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \> = 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and/or oxaliplatin (and EGFR inhibitor if known Ras wild type) |
| Name | Type | Description |
|---|---|---|
| NX-1607 | DRUG | Oral NX-1607 |
| Paclitaxel | DRUG | Paclitaxel IV |
Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from...
NX-1607 is an investigational small molecule being studied for the treatment of epithelial ovarian cancer. It is currently in Phase 1 clinical development as a monotherapy for adults with advanced malignancies, including epithelial ovarian cancer, among other solid tumors and hematologic malignancies.
NX-1607 is a small molecule developed by Nurix Therapeutics. Its molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated in a Phase 1 study for its safety and efficacy in advanced malignancies, including epithelial ovarian cancer.
NX-1607 is being developed by Nurix Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NRIX. The company is conducting a Phase 1 clinical trial of NX-1607 in adults with advanced malignancies.
NX-1607 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 study is actively recruiting participants to evaluate the drug in adults with advanced malignancies, including epithelial ovarian cancer.
NX-1607 is being studied in a single Phase 1 clinical trial with the identifier NCT05107674, titled "A Study of NX-1607 in Adults With Advanced Malignancies." This actively recruiting trial has an estimated enrollment of 345 participants and is being conducted in the United States and United Kingdom.
No alternative names for NX-1607 have been disclosed in the available clinical trial information. The drug is identified solely as NX-1607 in the ongoing Phase 1 study for advanced malignancies, including epithelial ovarian cancer.